Focused ultrasound holds promise in a large number of therapeutic applications. It has long been known that high-intensity focused ultrasound (HIFU) can kill tissue through coagulative necrosis. However, it is only in recent years that practical clinical applications are becoming possible, with the development of high-power ultrasound arrays and noninvasive monitoring methods. In the last decade, HIFU have been adapted and used to treat localized prostate cancer and it is now commercially available in Europe. In this article, preclinical studies and clinical development of prostate HIFU as well as early clinical results from our center and international studies are reviewed. Early results demonstrated that prostate HIFU is efficient to obtain local control for low-and intermediate-risk localized prostate cancer; however, long-term follow-up is still needed to estimate the efficacy of prostate HIFU in terms of specific cancer mortality. This makes HIFU a viable alternative in patients not candidate for radical therapy.
Introduction
High-intensity focused ultrasound (HIFU) is a technology that causes thermal tissue destruction with high precision and minimum damage to the surrounding structures. The principle is based on the physical effect of ultrasounds on tissues. Since its discovery in the early 1940s, it has been developed with the objectives of locally destroying tumours, and is particularly adapted to prostate cancer. First clinical studies with long-term results have been published showing that HIFU has become a viable modality to treat localized prostate cancer. Today, this technology is commercially available and is expanding throughout Europe.
The objective of this review is to describe the biophysic principles of HIFU, to highlight the different steps of its development and to give published information on clinical response and safety.
Basic principles of HIFU
Ultrasound wave emission is based on transducer vibration. Alternation of positive and negative electrical voltage on both sides of the transducer results in alternation of transducer thickness (dilatation and contraction) and therefore acoustical pressure in the coupling medium. [1] [2] [3] [4] [5] This acoustical pressure creates tissue movement (dilatation and contraction), the amplitude of which is directly related to the pressure level. As the tissue response is not perfectly elastic, energy is lost and converted into heat. The heat is homogeneously distributed along the ultrasound path if the transducer is not focused (Figure 1a ). By using a spherical-shaped transducer, the ultrasound beam is concentrated on the transducer focus point, resulting in a maximum of pressure concentrated at this point. As tissue heating is directly related to pressure maximum, the lesion is formed at the transducer focus (Figure 1b) . The tissue temperature increases at the focal area, resulting in an elementary lesion.
The creation of the lesion involves two main effects: a thermal effect directly related to the tissue temperature and a cavitation effect (presence of air bubbles in front of the transducer focus) due to alternation of large positive and negative acoustical pressure. The air bubbles pulsation absorbs acoustical energy and increases the tissue heating. The presence of cavitation bubbles in front of the transducer focus results in nonsymmetrical lesion positioning with respect to the transducer focus. The lesion extension is about 3/4 in front of the transducer focus and 1/4 beyond. The lesion formation is also related to the firing duration: the lesion starts at the transducer focus and progresses toward the transducer during the firing sequence (Figure 1c ). [6] [7] [8] HIFU was initially applied for the treatment of glaucoma and then on different models of animal liver, kidney, and bladder tumours. The prostate gland is the ideal candidate for HIFU treatment because of its location adjacent to the anterior aspect of the rectal wall. In addition, the prostate gland ultrasound structure and its relationship to the neighbouring structure have been extensively described. Therefore, the use of HIFU to treat prostate cancer was a very interesting concept from the beginning, and this model has become a priority in terms of clinical development. Nevertheless, before the first treatment on human prostate, preclinical studies were necessary to adapt the US generator to prostate tissue, to elaborate treatment controls and to show the efficacy of HIFU on prostate cancer on in vivo and in vitro prostate cancer models.
Preclinical prostate studies of HIFU
Application of HIFU to prostate cancer is the result of a long and sophisticated preclinical investigation. In addition to the application of HIFU to prostate tissue, investigators had to evaluate the method on different models in vivo and in vitro.
The carcinogenesis aspects were studied through the Dunning tumour model in Copenhagen rats. Two different sublines, varying in aggressiveness and metastatic potential, were subcutaneously implanted in adult male rats. The tumours were targeted with contact HIFU under anaesthesia. In all cases, tumours were totally destroyed by the treatment and the rate of metastasis was lower in the treated group. 9 With respect to the transrectal approach for HIFU delivery, the canine model showed the feasibility for transrectal prostate destruction without rectal wall damages, demonstrating the reliability of the focused ultrasound principle. For this experimentation, the targeting and the treatment systems were coupled, placed in the rectum, with an easy ultrasound localization of the prostate.
The tissue destruction by HIFU occurs at the focal point of the transducer. The dimensions of the focal area were 8 mm in length by 1.5 mm in diameter. Each shot consisted of a burst of ultrasound waves with a duration ranging from 1 to 4 s. By repeating the shots and moving the transducer between each pair of shots, a large volume of prostate could be treated. Temperature measurements showed that HIFU produces high temperature at the focal point as demonstrated in (Figure 2) . 10 In this series of experiments, the authors have demonstrated that large coagulation areas within prostate parenchyma could be obtained easily by HIFU and that prostate destruction could be obtained without 
Clinical development
Early clinical phase I experiments in humans were carried out on human prostate adenoma prior to adenomectomy, to ascertain the formation of irreversible lesions by means of transrectal HIFU. The device used combined a firing system and an imaging system. The firing system consisted of a power amplifier, a frequency generator, and a therapy transducer (diameter 35 mm) focused at 35 mm and working at 2.25 MHz. The imaging system was a standard transrectal ultrasound probe. Both probes were coupled together in the patient's rectum ( Figure 3 ). The patient was placed in a lateral position under epidural anaesthesia. The firing head was introduced into the rectum and the prostate was easily localized by means of the sectorial imaging probe. The coordinates of the target volume were sent to a computer that controlled the movements of the firing head. A motorized system controlled the movements of the firing head inside the rectum. The computer calculated the dosage of firing required for a volume fixed within the limits of the prostatic adenoma. All the parameters were entered in the computer: the dimension of the target, the dimensions of an elementary lesion induced by one burst, and the duration and the occurrence of the burst. Patients included in the phase I clinical study had a mean adenoma volume of 40 g. The HIFU treatment lasted for about 20 min; the adenoma was then surgically removed by a Millin procedure. In all, 12 patients were included and treated without major complications. Macroscopy showed that the lesion size within the prostate varied as a function of the ultrasound dose. In the three patients who received a dose stronger than that in the canine model, a homogeneous necrosis lesion with clear edges was observed with dimensions equal to or slightly greater than the theoretical target volume. In the five patients who had a lower dose equivalent to the one used on canine protocol, a nonhomogeneous coagulation necrosis was noted. Moreover, the rectal wall was controlled for all patients, and in four of them, the authors noted a slight alteration of the mucosae.
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The current HIFU devices
Since the first phase I clinical trials, the HIFU devices have evolved with improvement in the treatment accuracy, the ease of use, and the safety. Several machines are under development, two of them being used for the prostate cancer application: the last one is the Sonablate s device (Focus Surgery, IN, USA), with encouraging preliminary results recently published, 12 and the Ablatherm s device (EDAP SA, France), which was evaluated for the past 10 years in Europe, including feasibility, histological, and clinical efficacy studies with long-term results available (Figure 3 ).
Focused ultrasound development and prostate cancer application
The pilot studies investigating the use of HIFU/ Ablatherm s in the prostate cancer indication aimed to evaluate the treatment-related morbidity, in order to guide further technical development and to improve the treatment precision and safety. From 1993 to 1997, 44 patients were treated using the first device prototype (Ablatherm s 1). The overall morbidity was 31%. During this period of time, the prototype was modified with the implementation of a cooling system, the definition of the target volume, and the preservation of the rectal wall with a permanent check of the transducer-rectum distance and a safety ring to maintain the position of the probe in the rectum. With these additional safety features, the authors reported a complete response (negative biopsies and stable nadir PSA) for 61% of the study patients, while the global morbidity decreased from 50% in the 1993-1995 period to 16% in the 1996-1997 period. Most of these complications were related to the coagulative necrosis: inflammatory retention, bladder neck stenosis leading to prolonged retention. Investigators proposed to combine a transurethral resection of the gland performed immediately before or after the HIFU delivery. Other serious complications such as incontinence or urethrorectal fistula are less frequent (2/44 patients), but led to the implementation of additional safety features, particularly for the rectal wall preservation ( Figure 3) . 13 
Therapeutic effect
The histological efficacy of the HIFU treatment for prostate cancer was assessed in a clinical trial with HIFU HIFU to treat prostate cancer M Colombel and A Gelet delivery prior to radical prostatectomy, allowing a complete histology examination of the gland.
14 In this study, 17 patients scheduled for radical prostatectomy underwent a partial HIFU treatment (along with positive biopsies) an average of 8 days prior to surgery. Pathological analysis showed that the treated area was well individualized macroscopically. Prostate parenchyma presented with coagulation and haemorrhagic necrosis (Figure 4) , with sharp limits with normal untreated prostatic tissue. In five patients, residual tumour cells were isolated from the precapsular peripheral zone of the prostate and in 11 cases, residual tumour cells were found in the untreated anterior part of the gland. None of the treated areas showed evidence of residual cancer. Furthermore, coagulation necrosis was found extending few millimetres in periprostatic fat. Therefore, the authors concluded that HIFU was efficient on prostate cancer, with an immediate ablative effect on the treated tissue.
Response to treatment evaluation
In a clinical setting, prostate cancer response to HIFU is evaluated by post-treatment prostate-specific antigen (PSA) and biopsies. The nadir PSA is generally obtained within 3 months, so the first treatment efficacy assessment is justified from this follow-up timing. Biopsies and PSA measurements are performed in order to evaluate a complete response, that is, negative biopsies and stable PSA. These parameters are used to define the need for an additional treatment and to establish the overall response. Systematic sextant biopsies are made at 3 months in a mean residual prostate volume of 1975 s.d.g. In case of residual cancer, a new treatment is recommended regardless of the PSA level.
A magnetic resonance imaging (MRI) study was performed for some patients. Rouvière et al 15 showed that, using fat-saturated gadolinium-enhanced T1-weighted images, the treated area appeared as a hypodense zone surrounded by a peripheral rim of enhancement in all patients. A positive correlation was found between the volume of the hypodense zone measured at days 2-5 and the theoretical target volume. Moreover, MRI showed that the anterior part of the prostate was not reached by the ultrasound beam. However, no correlation was found between the MRI appearance of the treated area and the intensity of the necrosis or the presence of foci of residual cancer at 3 months (Figure 4) .
Results of the multicentric European study
Interim results from a European multicentric prospective single-arm treatment are available. Six investigational sites participated and 652 patients with clinically localized prostate cancer were recruited. The treatment consisted of a full prostate HIFU application. Follow-up included prostate biopsies at 3, 6, and 12 months and then every year or based on PSA relapse. PSA was evaluated every 3 months. The study started in 1995, and Results with the first 402 patients with a median follow-up of 407 days are available. The treatment efficacy was evaluated according to the stringent response criteria: response was quoted as complete if PSA was lower than 1 ng/ml and biopsies were negative; partial if PSA was more than 1 ng/ml or increasing with a negative biopsy; and failure if biopsies were positive. Interim results were based on post-treatment biopsy only. Taken all together, biopsy response rates were 87.2%; however, response rates varied according to pretreatment characteristics. Stratification in low risk (T1-T2 and PSAo10 ng/ml and Gleason o6), intermediate (T2b; PSA p20 or Gleason p7), and high risk (T2c or PSA 420 ng/ml or Gleason 8) showed biopsy responses of 92.1, 86.4, and 82.1%, respectively. An extended follow-up will be needed to correlate posttreatment biopsy response to the long-term response of the disease ( Figure 5 ). Longer term results from experienced sites are also available. In a recent report, Gelet and co-workers 16 presented results from 120 patients who were followed up for at least 36 months. In this series, the complete response rate, as defined by negative biopsies and a stable PSA at the nadir value, was 77.4%. Survival curves stratified with Gleason grade showed that in welldifferentiated carcinoma less than or equal to Gleason 6, the progression-free survival at 48 months is 85%, as opposed to 64% in case of grade 4 disease. In addition, survival curves show that after 2 y without recurrence, the probability of relapse as observed in the case of surgery (Figure 6 ).
Toxicity
The most serious reported complications are incontinence and urethrorectal fistula. Stress incontinence grade I and grade II are reported in 10.6 and 2.5%, respectively. 17, 18 Light incontinence generally resolved spontaneously or after appropriate management with medication and/or floor muscle training. Grade III incontinence was reported in 0.6-1.14% necessitating in most of them the placement of a urinary sphincter. Lesions to the urethral external sphincter were essentially observed at the beginning of the clinical application to patients with localized untreated prostate cancer. 
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Today, technology has considerably improved and incontinence rates have been dramatically reduced.
Urethrorectal fistula is considered the most serious complication given their difficult management. Urethrorectal fistulas, due to the destruction of the rectal wall during treatment, occurred in 0.9% of patients either before rectal cooling system or in patients with a large rectal wall or in patients with a history of rectal disease (surgery, recent anal fistula, radiotherapy). New treatment controls have been developed and improved in order to secure the rectal wall. In most of the cases, however, urethrorectal fistulae were treated by simple bladder catheter, although in other cases fibrin injection or surgery was necessary (Table 1) . In these cases, we treated our patients by a transanal approach (York Mason technique).
Urinary tract infections are reported in 13.8% of patients. Postoperative urinary retention is constant, due to local inflammation and resolve spontaneously in the majority of the cases in 5 days. Long-term retention has been described when using a suprapubic tube. Postoperative urinary retention has been considerably improved since the majority of patients are treated by previously limited endoscopic resection. Prolonged postoperative retention was also observed in relation to urethral stenosis in 3.6% of patients.
Erectile dysfunction after HIFU is observed in most of the patients. Total impotence varies from 22 to 69% (normal sexuality before treatment), and 16% of patients declared having normal erections with intercourse. Evaluation of post-treatment erectile dysfunction is not easy. On a routine basis, it is tempting to propose a treatment protocol with bundle preservation with a risk of incomplete treatment.
Discussion and conclusion
The therapeutic potential of ultrasound has been known for decades. The improvement of medical imaging and engineering allows focused ultrasound technology to be adapted for the surgical destruction of tissues, in particular for cancerous tumour destruction. Early results suggest that localized prostate cancer is an acceptable indication for HIFU.
The clinical evaluation of the HIFU option was performed in a limited number of investigational sites. Results appear convergent among the sites, and only long-term results will provide consistent and relevant data for specific and nonspecific mortality. As of today, several European centres are already treating patients who are not suitable candidates for surgery. The main advantages of this option is the single session delivery, with a low-cost disposable, and the possibility to repeat it with a second or even a third session if needed, thus delaying the hormone administration. 
